Alterity Therapeutics
ATHE
9 hedge funds and large institutions have $299K invested in Alterity Therapeutics in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 3 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
10% less funds holding
Funds holding: 10 → 9 (-1)
32% less capital invested
Capital invested by funds: $441K → $299K (-$142K)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$13.6K |
| 2 |
Millennium Management
New York
|
+$7.74K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
+$258 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$28.3K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$13K |
| 3 |
HF
HRT Financial
New York
|
-$6K |
| 4 |
Envestnet Asset Management
Chicago,
Illinois
|
-$2.53K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $241K | -$28.3K | -4,830 | -8% |
|
|
2
Envestnet Asset Management
Chicago,
Illinois
| $35K | -$2.53K | -432 | -5% |
|
|
TSS
3
Two Sigma Securities
New York
| $10K | +$13.6K | +2,319 | New |
|
|
4
Millennium Management
New York
| $6K | +$7.74K | +1,321 | New |
|
5
Geode Capital Management
Boston,
Massachusetts
| $5K | – | – | – |
|
|
PCA
6
Providence Capital Advisors
Charlotte,
North Carolina
| $1K | – | – | – |
|
|
SWM
7
Sugarloaf Wealth Management
Duluth,
Georgia
| $1K | – | – | – |
|
|
8
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$13K | -2,153 | Closed |
|
|
HF
9
HRT Financial
New York
| – | -$6K | -1,138 | Closed |
|
|
10
Osaic Holdings
Scottsdale,
Arizona
| – | +$258 | +44 | +116% |
|
ATHE Hedge Fund Activity: Q3 2022 in Review
9 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Alterity Therapeutics (ATHE) for Q3 2022, worth a combined $299K — down 32% from $441K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ATHE and 2 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.
The largest buyer was Two Sigma Securities, opening a new position worth an estimated $13.6K. The largest seller was Morgan Stanley, cutting an estimated $28.3K.
- 9 institutional investors held Alterity Therapeutics (ATHE) as of Q3 2022, down from 10 in Q2 2022.
- Funds reported $299K of Alterity Therapeutics stock for Q3 2022, down 32% quarter-over-quarter.
- 2 funds opened new Alterity Therapeutics positions in Q3 2022 and 3 closed out, a net change of -1 holder.
- The largest Alterity Therapeutics buyer in Q3 2022 was Two Sigma Securities, an estimated $13.6K added.
- The largest Alterity Therapeutics seller in Q3 2022 was Morgan Stanley, an estimated $28.3K sold.
Based on aggregated 13F filings for Q3 2022.